conducted a bibliometric review and suggested that for early gastric cancer, low expression of IL-2 and IL-17 indicates a favorable prognosis, whereas, in advanced gastric cancer, the expression of these cytokines does not significantly affect survival rates, implying a potential influence on prognosis at the time of onset (36). This evidence concerns the gene IL2 and gastric cancer.